When the #BreastCancerAwarenessMonth pink is packed away, many women don't think about their prevention plans again until next year. Learn how CancerIQ can help you identify, assess, & manage the high-risk patients that need more than an annual screening. bit.ly/3SyqVVv

Today is #GeneticCounselorAwarenessDay! At CancerIQ, we are grateful for the essential role cancer genetic counselors play in helping patients precisely treat, predict, pre-empt, and prevent this disease. bit.ly/3FTl1He #GeneChat #AheadOfCancer #PrecisionPrevention

Patient advocate Allison Rosen, MS at American Cancer Society shares her story & the importance of a #precisionprevention approach for high-risk patient management: "Having Crohn’s disease put me at greater risk for colorectal cancer & as a result, every year, I have a diagnostic colonoscopy."

We're thrilled to announce AssuranceLab SOC 2 Type 2 Compliance, demonstrating that we have undergone rigorous testing & are a trusted platform for empowering health systems to scale genetically informed cancer prevention, treatment, & survivorship care. prweb.com/releases/cance…

A new study co-authored by Catharine Wang, Boston University School of Public Health and Haibo Lu, CancerIQ shows point-of-care genetics may improve access, uptake, and reduce racial disparities across broad patient populations. #SABCS23 #BCSM #GeneChat bit.ly/4a9utny

.@CancerX is conducting its first demonstration project to merge data assets, and collaborating with industry partners (including CancerIQ!) to build comprehensive real-world datasets in a way that’s never been done before in oncology. Learn more: bit.ly/3tmfxlt

1/ Welcome to #CGAIGCJS November Tweetorial on the Making #Genetic Testing Accessible (MAGENTA) Trial by #CGAIGC Comms Cttee member asaf maoz ➡️The full article from JAMA Oncology can be found at 👉tinyurl.com/bdh5t6jv 🧵 #HereditaryGICancer

Happy, Healthy New Year 2024 from all of us at CancerIQ! Together, we can stay ahead of cancer, bringing hope and health to our communities. Here's to a year of breakthroughs, health, and progress! #aheadofcancer #precisionprevention

New germline genetic testing guidelines: All women with breast cancer diagnosis under the age of 65 should be offered germline genetic testing. They don’t need to meet any additional criteria. Thank you ASCO for the opportunity to draft these guidelines. ascopubs.org/doi/full/10.12…

The American Cancer Society Cancer Facts & Figures 2024 report is here. With breast, prostate, colorectal (ages 0-54), and cervical (ages 30-44) cancers on the rise, it's important to get screened. Hear more from @AmerCancerCEO. Full report: amercancer.co/cff24

A much larger pool of patients now requires access to #genetictesting given ASCO's expanded BRCA1/2 mutation testing recommendations for all #bscm patients <65 years old. It's imperative we equip clinical teams with the tools to support increased volumes. bit.ly/48E6dbU

Q&A: Partnering with providers for #cancer #prevention - CancerIQ provides personalized care plans to help providers detect cancer early and prevent progression of the disease, says Feyi Ayodele, founder and CEO of CancerIQ. mobihealthnews.com/news/qa-partne…

CancerIQ believes that everyone, regardless of where they live, deserves the chance to prevent, detect & treat cancer effectively. Help us make our mission a reality by joining our team. bit.ly/49cNpk6 #WorldCancerDay #CloseTheCareGap #AheadOfCancer #PrecisionPrevention

There's nothing sweeter than saving lives through #precisionprevention, #earlydetection, and treatment! Happy Valentine's Day from team CancerIQ to every provider using genetic information to empower patients and get #aheadofcancer! Learn more: bit.ly/3woogEM

For #LynchSyndromeAwarenessDay this is your reminder that: 💠 Lynch syndrome is common (1:279 individuals) 💠 Lynch syndrome is actionable (increased surveillance/prevention options lead to better outcomes) 💠 Lynch syndrome is underdiagnosed (most people are not aware that they

CancerIQ seeks health system participants in large-scale research effort: "Validating Applications for Long-term Utility and Enhanced ROI" (VALUE) in Cancer Risk Programs Study, to document the ROI of digital interventions for genetically informed care. bit.ly/44dbRjP

Congratulations to our #CASTUS portfolio company, CancerIQ, for being named one of the World's Best Digital Health Companies in 2024 by Newsweek and Statista! 🎉 Read full article: bit.ly/4b6tdBH #ClevelandAvenue #NewsWeek #AheadOfCancer

Beyond traditional clinic settings, there lies a vast opportunity to connect with individuals who might not be aware of their cancer risk or precision prevention opportunities. Learn more about CancerIQ's campaign-based screening: bit.ly/3KlUt3e #precisionprevention

ICYMI: July's highlight was our webinar with Nebraska Medicine's Cancer Survivorship & Risk & Prevention Director Rachael Schmidt, APRN: "What is Campaign-Based Risk Assessment & How Does It Drive Cancer Screening Compliance?" bit.ly/4d8g9wz #precisionprevention #lungcancer

Data shows CancerIQ Reach closes gap between eligibility and participation in payer-supported, standard and supplemental screenings, leads to early cancer diagnoses and promotes health system loyalty story.cd/AAYYMz